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Abstract
Understanding the complexity of changes in differentiation and cell survival in hepatocellular carcinoma (HCC) is essential
for the design of new diagnostic tools and therapeutic modalities. In this context, we have analyzed the crosstalk between
transforming growth factor β (TGFβ) and liver X receptor α (LXRα) pathways. TGFβ is known to promote cytostatic and
pro-apoptotic responses in HCC, and to facilitate mesenchymal differentiation. We here demonstrate that stimulation of the
nuclear LXRα receptor system by physiological and clinically useful agonists controls the HCC response to TGFβ.
Specifically, LXRα activation antagonizes the mesenchymal, reactive oxygen species and pro-apoptotic responses to TGFβ
and the mesenchymal transcription factor Snail mediates this crosstalk. In contrast, LXRα activation and TGFβ cooperate in
enforcing cytostasis in HCC, which preserves their epithelial features. LXRα influences Snail expression transcriptionally,
acting on the Snail promoter. These findings propose that clinically used LXR agonists may find further application to the
treatment of aggressive, mesenchymal HCCs, whose progression is chronically dependent on autocrine or paracrine TGFβ.
Introduction
Hepatocellular carcinoma (HCC) is the fifth and seventh
cause of cancer worldwide in men and women, respectively,
and the third most common cause of cancer death, with
leading causative agents being chronic infections by hepa-
titis B virus and, at a lower degree, hepatitis C virus [1,2]. In
HCC, as in other malignancies, transforming growth factor
β (TGFβ) has tumor-suppressive and -promoting effects
depending on disease stage and microenvironmental con-
text. As tumor suppressor, TGFβ inhibits cell proliferation
by inducing transcription of the cell cycle inhibitor genes
p15INK4b and p21CIP1, and by inducing differentiation,
senescence, and apoptosis. TGFβ also hinders mitogen
production from stromal cells, impairing inflammatory
cytokine secretion from lymphocytes and macrophages [1].
As tumor promoter, TGFβ permits HCC cell proliferation
and migration due to desensitization or acquired resistance
of hepatocytes to its tumor-suppressive actions [3]. TGFβ
induces epithelial–mesenchymal transition (EMT) and
anti-apoptotic gene (e.g., BCL2 and MCL1) expression,
stimulates synthesis and release of metalloproteinases and
pro-fibrotic molecules, thus enhancing invasion and angio-
genesis [1]. EMT is driven by the transcription factor Snail
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in HCC, which unleashes an invasive phenotype, stem-like
functions, and cell survival [2,4].
TGFβ mediates the production of reactive oxygen spe-
cies (ROS), contributing either to survival or to apoptosis
[5]. In rat fetal hepatocytes, ROS induction by TGFβ occurs
before the loss of mitochondrial membrane potential,
the release of cytochrome C from mitochondria, and
the activation of caspase 3, leading to apoptosis [6,7].
Anti-apoptotic ROS are produced by the NADPH oxidase
(NOX) 1, and promote epidermal growth factor receptor
signaling [5,8]. Under chronic liver cirrhosis, hepatocytes
develop resistance to TGFβ-induced apoptosis, a process
that is also dependent on ROS, generated by NOX4 [9,10].
Liver X receptors (LXRα/NR1H3 and LXRβ/NR1H2)
are transcription factor members of the nuclear hormone
receptor family [11]. Oxysterols, derivatives of cholesterol,
and its biosynthetic intermediates, such as desmosterols and
24-(S)-25 epoxycholesterol, are physiological ligands and
regulate the LXRs [11]. LXRα is expressed in tissues with
high metabolic rate, including liver and adipose tissue and
macrophages, whereas LXRβ is ubiquitously expressed
[11]. LXRs play dual roles in cancer, by suppressing pro-
liferation of cancer cells, or by inhibiting the immunological
response via oxysterol production, allowing tumors to
escape from immune surveillance [12]. Nonetheless, little
evidence exists about the role of LXR and its crosstalk with
TGFβ during liver cancer progression.
We recently reported a new mechanism by which LXRα
and its agonists counteract TGFβ signaling in fibroblasts,
thus blocking their final stage of differentiation into myo-
fibroblasts [13]. Here, we analyzed possible antagonism
between TGFβ and LXRα pathways that could affect phy-
siological processes in HCC cells. We report such negative
interaction, which, unexpectedly, is mediated by Snail, a
regulator of the EMT program.
Results
Oxysterols interfere with TGFβ-induced
mesenchymal protein expression in HCC
Based on a high-throughput screen for EMT inhibitors, we
established that the LXRα/β agonists T0901317, WYE672,
and GW3965 antagonize TGFβ-mediated myofibroblast
differentiation, whereas GSK3987, an established LXRα/β
antagonist, had neutral or the opposite effect [13]. Along
with the oxysterols, ivermectin (a farnesoid-X-receptor
agonist) and GGsTOP (a γ-glutamyl-transpeptidase inhi-
bitor) were identified as potential inhibitors of EMT and
myofibroblast differentiation [13]. These compounds were
tested in combination with TGFβ1 stimulation for 48 h on
two HCC models, the epithelial Hep3B and the
mesenchymal Snu449 cells [14], in order to assess whether
they could revert TGFβ-induced EMT. EMT was analyzed
by loss of expression of the epithelial E-cadherin and
induction of the mesenchymal proteins fibronectin and
vimentin (Fig. 1a). T0901317, WYE672, and GW3965 only
slightly decreased the TGFβ-induced expression of fibro-
nectin and essentially failed to restore E-cadherin expres-
sion in Hep3B cells (Fig. 1a; for simplicity, each control
condition (first lane) shows relative normalized expression
set to 1, corresponding to either strong basal expression (E-
cadherin) or low basal expression (fibronectin), in order to
compare differences in expression between various experi-
mental conditions and the control. The densitometric
intensity in the control condition represents the relative
abundance of each distinct protein in the respective cell
line.). TGFβ signaling potently downregulated E-cadherin
and upregulated fibronectin, whereas vimentin, which was
already expressed by the mesenchymal Snu449, was further
increased (Fig. 1a; for simplicity, the measurable basal
levels of E-cadherin, weak basal levels of fibronectin, and
appreciable basal levels of vimentin appear as 1 in the
quantification of the figure, whereby 1 corresponds to sig-
nificantly different absolute expression levels. Compare the
low levels of E-cadherin (< 1× 10−4 relative units) after
TGFβ1 stimulation and the similarly low levels after use of
various compounds in the presence of TGFβ1; or the high
levels of fibronectin (21) and vimentin (3) after
TGFβ1 stimulation and the similarly high levels after use of
most of the compounds in the presence of TGFβ1.). Thus,
the LXR agonists could not restore E-cadherin expression in
mesenchymal Snu449 cells, but decreased the expression of
TGFβ-induced fibronectin and vimentin (Fig. 1a). The
results agree with our high-throughput chemical screen
[13], and clarify that oxysterols cannot effectively induce
mesenchymal to epithelial transition, however, they antag-
onize TGFβ-dependent regulation of mesenchymal genes.
Impact of TGFβ on LXRα/β expression in HCC cells
We then assessed expression of the LXRα/β genes after
TGFβ stimulation, using SERPINE1 as a positive control. In
Hep3B cells, LXRα/NR1H3 expression was unresponsive to
TGFβ stimulation and LXRβ/NR1H2 was upregulated after
16 and 24 h stimulation (Fig. 1b). In Snu449 cells, both
LXRα and LXRβ mRNAs were upregulated (Fig. 1c), LXRα
protein expression was enhanced, while LXRβ protein
expression remained relatively constant upon TGFβ stimu-
lation (Fig. 1d); inhibitors of p38 (SB203580), JNK
(SP600125), and MEK (PD184352) kinases of the MAP-
kinase family suppressed the LXRα induction in Snu449
cells, whereas the p38 inhibitor (SB203580) enhanced
LXRα levels in the absence of TGFβ stimulation, possibly
indicating a stabilizing effect on the LXRα protein (Fig. 1e).
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Although the quantification of LXRα/β mRNA and protein
levels reports basal level equal to 1 (Fig. 1b–e), this level
varies from cell type to cell type and for each LXR member;
these differences at the endogenous basal level can be
observed in the immunoblots of Fig. 1d, e. In other epi-
thelial HCCs, PLC/PRF5 and HUH7, only LXRβ expression
was affected by TGFβ stimulation at specific time points,
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Snail links LXR to TGFβ actions in HCC
weak level of regulation could be detected for LXRα and
slightly stronger for LXRβ expression after TGFβ treatment
(Supplementary Fig. 1). We conclude that TGFβ can reg-
ulate LXR levels in certain cell models, but this is not a
universal or particularly strong response of HCC to TGFβ.
LXRα activation antagonizes TGFβ-induced Snail
expression and nuclear accumulation
The expression of EMT transcription factors and stem cell
markers was analyzed in order to assess whether LXRα
affected the expression of well-characterized TGFβ target
genes (data not shown). Transient LXRα silencing in
Snu449 cells caused a significant reduction in the TGFβ-
induced expression of SNAI1 (Snail) (Fig. 2a). On the
contrary, LXRα overexpression especially in combination
with TGFβ stimulation induced Snail mRNA and protein
levels (Fig. 2a, b). Activating endogenous LXR with
T0901317 suppressed the TGFβ-induced Snail mRNA and
protein levels in Snu449 cells (Fig. 2c, d). An independent
LXR agonist (GW3965) exhibited the same antagonistic
effect (Fig. 2d), suggesting that LXR might interfere with
the ability of TGFβ to induce Snail expression in
mesenchymal HCC cells. This result was confirmed in
additional mesenchymal HCC cells, HLE and HLF, but was
not observed in Snu423 cells, or in the epithelial HCC cells
PLC/PRF5 and HUH7 (Supplementary Fig. 2).
Stimulating Snu449 cells with TGFβ for 3 h caused a
marked nuclear accumulation of Snail protein (Fig. 2e). Co-
administration of T0901317 with TGFβ significantly
decreased Snail nuclear abundance (Fig. 2e), in agreement
with the negative effect on Snail mRNA and protein levels
(Fig. 2c, d). Interestingly, the relative distribution of Snail
between cytosol and nucleus remained unchanged, but the
combined treatment with TGFβ and T0901317 for 24 h
decreased Snail protein amounts primarily in the nucleus
(Fig. 2f). These observations suggested that the combina-
tion treatment might affect Snail transcription rather than its
nuclear translocation or stabilization.
LXRα exhibits antagonistic effects over TGFβ on the
Snail promoter
To explore transcriptional mechanisms, we employed pro-
moter activation assays in HepG2 cells as a representative
HCC cell line that is easy to transfect. In HepG2 cells
transfected with the LXR-specific responsive luciferase
reporter ABCA-luc, stimulation of cells with the two LXR
agonists (T0901317 and WYE7672) enhanced reporter
activity (Supplementary Fig. S3a); ABCA-luc correlated
with endogenous ABCA and SREBP1C gene induction by
these agonists in Snu449 cells (Supplementary Fig. S3b).
ABCA and SREBP1C are established gene targets of the
LXRs in many cell types. In contrast, the LXR antagonist
GSK3987 had a weak negative effect on ABCA-luc reporter
activity or on endogenous gene expression (Supplementary
Fig. 3a, b). To provide specificity of LXR agonist signaling
via LXRα, we transiently silenced the endogenous LXRα,
causing a lack of response of the ABCA-luc reporter or
significant reduction in the response of the endogenous
genes ABCA and SREBP1C to the agonist T090137
(Fig. 3a, Supplementary Fig. 3c, d). Monitoring the effi-
ciency of LXRα silencing also demonstrated a significant
induction of LXRα mRNA by the agonist T0901317 (Sup-
plementary Fig. 3c, d). Corroborating these results, LXRα
overexpression after transfection of HepG2 cells with the
pCMX-LXRα vector [15] activated the ABCA-luc promoter
and even better after T0901317 stimulation (Fig. 3a). In
contrast, a C-terminal deletion mutant of LXRα lacking its
ligand-binding domain but retaining DNA-binding and
transactivation functions [15], exhibited weak transactiva-
tion of the ABCA-luc promoter and lack of significant
response to T0901317 stimulation (Fig. 3a).
The effect of LXRα silencing and overexpression was
determined using an ~900 bp-long human Snail promoter
fragment cloned upstream of the luciferase reporter [16].
Snail-luc activity was readily measurable in the HCC cells;
Fig. 1 TGFβ regulates LXRα expression in the mesenchymal cell line
Snu449. a Hep3B (left) and Snu449 (right) cells were treated with the
indicated compounds (10 μM) and TGFβ1 (5 ng/ml) for 24 h. The
TGFβ type I receptor kinase inhibitor LY2157299 was added at a final
concentration of 2 μM for 24 h as a potent positive control. The
expression of the indicated proteins was analyzed by immunoblotting.
Experiments performed in biological duplicate. Densitometric quan-
tification is provided below each lane. Results indicated as <0.01
represent a densitometric intensity between 0.0045 and 0.0082; results
indicated as <1× 10−4 mean a densitometric intensity between
0.00002 and 0.00009; basal expression levels set as 1 correspond to
either strong detectable protein levels (E-cadherin) or very low to
almost undetectable levels (fibronectin). b, c Hep3B (b) and Snu449
(c) cells were treated for different time periods with TGFβ1 (5 ng/ml).
The expression of LXRα, LXRβ, and SERPINE1/PAI1 genes was
assessed via real-time PCR and normalized to the expression of
GAPDH. Mean± SD values are plotted, and basal expression levels
set to 1 correspond to different absolute levels of expression for each
mRNA. Experiments performed in biological triplicate, each of them
in technical triplicate. d Snu449 cells were treated with TGFβ1 (5 ng/
ml) for the indicated time periods. The expression of the indicated
proteins was analyzed by immunoblotting. Experiments performed in
biological triplicate. Densitometric quantification is provided graphi-
cally, and basal expression levels set to 1 correspond to different
absolute levels of expression for each LXR member. e Snu449 cells
were treated with vehicle or TGFβ1 (5 ng/ml) for 24 h. SB203580 (p38
inhibitor, 10 µM), SP600125 (JNK inhibitor, 10 µM), and PD184352
(MEK inhibitor, 0.5 µM) were added 1 h prior to TGFβ1 addition. The
expression of the indicated proteins was visualized via immunoblot-
ting. Experiments performed in biological triplicate. Densitometric
quantification is provided graphically. Statistical significance was
assessed by one-way (b–d) or two-way (e) Anova. Significance was
assigned as *p< 0.05, **p< 0.01, ***p< 0.001. All immunoblots
indicate molecular size markers in kDa
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it was significantly abrogated after LXRα silencing and was
induced after LXRα overexpression (Fig. 3b). TGFβ sti-
mulation induced Snail-luc activity by twofold (Fig. 3c).
LXRα overexpression combined with TGFβ stimulation
exhibited an even stronger stimulatory effect on the Snail
promoter (Fig. 3c). However, concomitant stimulation of
Snail links LXR to TGFβ actions in HCC
the transfected cells with T0901317 resulted in a significant
decrease of Snail-luc activity (Fig. 3c). This result suggests
that only when LXRα is in an active conformation, as
enabled by the binding of T0901317 to the LXRα ligand-
binding domain, can antagonize the transcriptional effect of
TGFβ signaling on Snail. To confirm this finding by an
independent assay, we co-expressed Smad3 and Smad4
(mimicking stimulation by exogenous TGFβ), which
induced Snail-luc activity; when the cells were treated with
T0901317 to activate endogenous LXRα, a comparable
decrease in Snail-luc activity was observed (Fig. 3d). To
test the hypothesis that ligand-bound LXRα antagonizes
TGFβ signaling on the Snail promoter, we repeated the
Snail-luc experiments using the truncated LXRα mutant that
lacks ligand-binding domain. In contrast to full-length
LXRα, the truncated mutant failed to enhance Snail-luc
activity beyond the effect of Smad3/4 and TGFβ, whereas
T0901317 lost its ability to suppress the inducibility of
Snail-luc by TGFβ when administered in the presence of the
truncated LXRα mutant (Supplementary Fig. 3e,
nonsignificant (ns) difference). During the course of these
experiments, we reproducibly observed that whereas
T0901317 stabilized LXRα protein levels, TGFβ/Smad
signaling destabilized LXRα (Supplementary Fig. 3e, bot-
tom). Taken together, these results suggest that the antag-
onistic effect between TGFβ and LXRα signaling pathways
on Snail occur at the promoter and transcriptional level.
The antagonistic role of LXRα on Snail induction by
TGFβ negatively influences the mesenchymal
properties of HCC
Combination treatment with TGFβ and T0901317 (Fig. 4a)
or GW3965 (Fig. 4b) decreased the Snail-dependent, TGFβ-
induced expression of the mesenchymal protein N-cadherin
[17]. Co-administration of TGFβ and T0901317 also
diminished the localization of N-cadherin at the adherens
junctions of the mesenchymal cells, as confirmed by
immunocytochemistry (Fig. 4c). EMT is associated with
reorganization of the actin cytoskeleton to abundant stress
fibers; the combination treatment significantly decreased the
formation of actin stress fibers induced by TGFβ stimulation
(Fig. 4d). A systematic decrease of mesenchymal features of
the Snu449 cells takes place due to the antagonism occur-
ring between the TGFβ and LXR pathways, which correlate
with the decrease in Snail expression.
We evaluated whether the described results were
dependent on LXRα and consequently on its action on Snail
(Fig. 5). The decrease in Snail expression induced by TGFβ
and T0901317 co-treatment was rescued after knockdown
of LXRα, however the same effect could not be observed
for N-cadherin, although a clear trend was recorded
(Fig. 5a, statistical analysis). The decrease in N-cadherin
localization at adherens junctions and decrease in stress
fiber formation by TGFβ and T0901317 co-administration
were also rescued when LXRα was silenced (Fig. 5b, c).
Thus, the antagonistic effect is dependent on the presence of
LXRα, and LXRα activation concomitant to proficient
TGFβ causes a decrease in Snail levels, negatively affecting
mesenchymal differentiation.
TGFβ and LXRα additively inhibit proliferation of
epithelial HCC Hep3B
The epithelial Hep3B cells can undergo cell cycle arrest and
apoptosis after TGFβ stimulation, thus resulting in a
decrease in cell viability [18]. Co-administration of TGFβ
and T0901317 for 48 h in Hep3B cells resulted in even
further decreased cell viability when compared to the TGFβ
effect alone, as assessed by MTS viability assays (Fig. 6a).
The same trend was observed when Hep3B cell prolifera-
tion was estimated by Ki67 staining (Fig. 6b). TGFβ
treatment caused a decrease in cyclin E and an increase in
Fig. 2 LXRα activation antagonizes TGFβ-induced Snail expression. a
Snu449 cells were transfected with 30 nM of non-targeting siRNA
control or LXRα targeting siRNAs and stimulated by TGFβ1 (5 ng/ml)
for 24 h in starvation medium. Expression of the indicated genes was
assessed by real-time PCR. Mean ± SD values are plotted, and basal
expression levels set to 1 correspond to the same absolute levels of
SNAI1 mRNA expression. Experiments performed in biological
duplicate, each of them in technical triplicate. b Snu449 were trans-
fected with 1 μg of pCDNA3 or pCMX-LXRα plasmid, and treated
with TGFβ1 (5 ng/ml) for 24 h in starvation medium. Expression of the
indicated proteins was assessed by immunoblotting. Experiments
performed in biological triplicate. Densitometric quantification is
provided graphically, and basal expression levels set to 1 correspond
to different absolute levels of protein expression, as visualized on the
immunoblots. c Snu449 cells were treated with TGFβ1 (5 ng/ml) with
or without T0901317 (5 μM) in starvation medium for 24 h; expression
of SNAI1 mRNA was assessed by real-time PCR. Mean ± SD values
are plotted. Experiments performed in biological triplicate, each of
them in technical triplicate. d Snu449 cells were treated in starvation
medium for 24 h; TGFβ1 (5 ng/ml) was administered with or without
LXR agonist (T0901317 or GW3965, 5 μM). Expression of Snail was
determined by immunoblotting. Experiments performed in biological
quadruplicate. Densitometric quantification is provided graphically,
and basal expression level set to 1 corresponds to almost undetectable
absolute level of Snail expression, as visualized on the immunoblot. e
Snu449 cells were immunostained for Snail and DAPI after 3 h of the
indicated treatments. Snail is represented in green, DAPI staining in
blue. Bars represent 40 µm. Quantification of the percent of Snail-
positive nuclei is graphed as mean ± SD values. Experiments per-
formed in biological triplicate. f Snu449 cells were starved and treated
as specified. Nuclear fractionation assay was performed and abun-
dance of the indicated proteins was assessed by immunoblotting.
Experiments performed in biological duplicate. Densitometric quan-
tification is provided graphically, and basal expression levels set to 1
correspond to the cytoplasmic levels of Snail protein expression, as
visualized on the immunoblot. Statistical significance was assessed by
two-way (a, b) or one-way (c–f) Anova. Significance was assigned as
*p< 0.05, **p< 0.01, ***p< 0.001. All immunoblots indicate
molecular size markers in kDa
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p21CIP1 protein expression; these effects were even further
enhanced by combination treatment with TGFβ and
T0901317 (Fig. 6c), explaining their effects on cell pro-
liferation (Fig. 6a, b). These results define how co-
activation of TGFβ and LXRα pathways enhance Hep3B
cytostasis, with a strong blockage of Hep3B cells in the G1
phase, as suggested by strong decrease in Ki67 staining,
decrease in cyclin E, and increase in p21CIP1 expression.
Snail links LXR to TGFβ actions in HCC
LXRα negatively regulates TGFβ-mediated
apoptosis, inducing pro-survival genes
We also asked whether the co-treatment with TGFβ and
T0901317 affected the apoptotic pathway in Hep3B cells.
Propidium iodide (PI) staining, which marks cells in late
apoptosis, suggested that the combination treatment sig-
nificantly decreased cell death induced by TGFβ (Fig. 7a).
Corroborating results were obtained by quantifying caspase
3 cleavage, which is indicative of the early apoptotic
response, both in epithelial Hep3B and in mesenchymal
Snu449 cells (Fig. 7b). Apoptosis in response to TGFβ also
involves antagonism against pro-survival signals of the
AKT pathway [2,4]. Accordingly, whereas TGFβ exhibited
weak ability to suppress AKT signaling, as measured by
phosphorylation of the AKT kinase at Ser473,
T0901317 strongly induced AKT phosphorylation, and co-
treatment with TGFβ and T0901317 caused an intermediate
level in phosphorylated AKT, attesting to the antagonism
between these two pathways (Fig. 7c).
In addition to mediating apoptosis, TGFβ can induce the
expression of pro-survival and anti-apoptotic proteins, such
as BCL-XL, BCL2, MCL1, and XIAP, in conjunction with
the acquisition of resistance mechanisms to TGFβ-induced
apoptosis [19]. Indeed, the mRNA levels of the pro-survival
genes BCL2 and MCL1 were increased by TGFβ, and were
further enhanced when TGFβ was co-administered with
T0901317 in Hep3B cells, suggesting an adaptive
mechanism of resistance against apoptosis (Fig. 7d).
Under the same conditions, TGFβ treatment increased
ROS production in Hep3B cells by 30%, and this effect was
significantly diminished when the LXR pathway was acti-
vated together with TGFβ signaling (Fig. 7e). In order to
define the molecular determinant of this biological effect,
the expression of the enzyme NOX4, previously linked to
TGFβ-induced ROS (see introduction), was assessed. TGFβ
induced NOX4 mRNA, while the combination treatment
significantly decreased it (Fig. 7f). We conclude that TGFβ
and T0901317 cooperate in antagonizing pro-apoptotic
responses, by decreasing NOX4 and ROS levels and by
enhancing pro-survival gene expression. These results
suggest that active LXRα signaling in the presence of TGFβ
causes a proliferative blockage with simultaneous resistance
to TGFβ-induced apoptosis in HCC cells.
Snail does not influence the apoptotic response but
mediates pro-survival gene expression
The decreased Hep3B cell survival observed upon TGFβ and
T0901317 co-administration was not regulated by Snail, as
assessed by MTS and caspase 3 cleavage assays (Fig. 8a, b)
after Snail silencing (Fig. 8f). Snail silencing could slightly
but significantly rescue the decrease in ROS production
during the combination treatment (Fig. 8c), and the regula-
tion of the NOX4 gene (Fig. 8d). On the contrary, expression
of the pro-survival genes BCL2 andMCL1 was dependent on
Snail, since silencing Snail significantly abrogated BCL2 and
MCL1 induction under co-treatment conditions (Fig. 8e).
These data suggest that the LXRα agonist counteracts TGFβ
signaling leading to apoptosis and requires Snail to induce
expression of anti-apoptotic genes and to mediate part of its
pro-survival signals, while at the same time, the combina-
torial treatment activates other survival pathways. Thus, Snail
appears to function as a central regulatory node to fine tune
the balance between cell proliferation and apoptosis in HCC.
Discussion
Oxysterols decrease the mesenchymal properties of fibro-
blasts, suggesting that LXR may antagonize pro-fibrotic
Fig. 3 The antagonistic effect of LXRα with regard to TGFβ-induced
Snail expression occurs at the promoter level. a HepG2 cells were
simultaneously transfected for 48 h with ABCA1-luc reporter, β-gal
plasmid, and siControl non-targeting or siLXRα targeting siRNA at a
final concentration of 30 nM (upper graph) or empty vector pCDNA3,
pCDNA3-LXRα full length, or pCDNA3-LXRα trunc (bottom graph).
Cells were treated in starvation medium with T0901317 (T09, 5 μM)
for 24 h, prior to luciferase and β-galactosidase activity detection.
Mean± SD of normalized activity values are plotted, and activity
levels set to 1 correspond to the mock (siCtrl or pCDNA3) condition in
the presence of DMSO (vehicle), which exhibited different absolute
activity levels. Experiments performed in biological triplicate, each of
them in technical quadruplicate. Immunoblotting for detection of
MYC-tagged LXRα full length or MYC-LXRα trunc together with
GAPDH is provided as control. b HepG2 cells were simultaneously
transfected with a siControl non-targeting or siLXRα targeting siRNA
at a final concentration of 30 nM and b pCDNA3 or pCMX-LXRα and
Snail-luciferase reporter plasmids for 48 h prior to luciferase and β-
galactosidase activity analysis. Mean± SD of normalized activity
values are plotted, and activity levels set to 1 correspond to the mock
(siCtrl or pCDNA3) condition, which exhibited different absolute
activity levels. Experiments performed in biological triplicate, each of
them in technical triplicate. c HepG2 cells were transfected with
pCDNA3 or pCMX-LXRα plasmids and Snail-luciferase reporter for
48 h, then treated in starvation medium with TGFβ1 (5 ng/ml) with or
without T0901317 (T09, 5 μM) for 24 h, prior to luciferase and β-
galactoside activity detection. Mean± SD of normalized activity
values are plotted, and activity levels set to 1 correspond to the mock
(pCDNA3) condition in the presence of DMSO (vehicle). Transfected
proteins were visualized by immunoblotting. Experiments performed
in biological duplicate, each of them in technical quadruplicate. d
HepG2 cells were transfected with pFlag-Smad3 and -Smad4 and
Snail-luciferase reporter plasmids, then cells were treated with
T0901317 (T09, 5 µM) for 24 h prior to luciferase and β-galactosidase
activity assessment. Mean ± SD of normalized activity values are
plotted, and activity levels set to 1 correspond to the mock (pCDNA3)
condition in the presence of DMSO (vehicle). Experiments performed
in biological triplicate, each of them in technical triplicate. Immuno-
blotting for detection of Smad3 is provided as control. All immuno-
blots indicate molecular size markers in kDa. Statistical significance
was assessed by two-way (a, c), one-way (d) Anova, or unpaired T-test
(b). Significance was assigned as **p< 0.01, ***p< 0.001
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responses to TGFβ [13]. By focusing on HCC, we identified
the transcription factor Snail, as a molecular link of the
LXR-TGFβ crosstalk. The new data suggest important
actions of LXR during late stages of HCC development,
characterized by mesenchymal, aggressive phenotypes.
Analysis of LXRα and LXRβ gene expression regulation
by TGFβ signaling, provided data of relatively weak, time-
dependent, and cell type-dependent regulation (Fig. 1,
Supplementary Fig. 1). LXRβ was regulated by TGFβ sig-
naling more reproducibly (Fig. 1, Supplementary Fig. 1), an
observation whose biological significance we have not yet
addressed. LXRα expression was regulated by MAP-kinase
signaling either at basal or TGFβ-induced levels (Fig. 1e).
Thus, TGFβ signaling in certain, but not all HCCs, can
regulate LXRα/β gene expression.
We examined the link between LXR, TGFβ signaling,
and Snail expression, since Snail is an important regulator
in both carcinoma cells that undergo EMT and in fibroblasts
that respond to TGFβ [20]. In mesenchymal HCC cells,
LXRα positively contributed to Snail expression; however,
LXRα activation by oxysterols suppressed TGFβ-induced
Snail expression (Fig. 2, Supplementary Fig. 2). All
Fig. 4 The antagonistic role of LXRα on TGFβ and Snail negatively
influences the mesenchymal properties of Snu449 cells. Snu449 cells
were treated with TGFβ1 (5 ng/ml) with or without LXR agonist
(T0901317 or GW3965, 5 μM) in starvation medium for 24 h. a, b
The expression of the indicated proteins was assessed by immuno-
blotting. All immunoblots indicate molecular size markers in kDa.
Experiments performed in biological quadruplicate. Densitometric
quantification is provided graphically and basal expression levels set
to 1 correspond to the different levels of N-cadherin protein
expression, as visualized on the immunoblots. Statistical significance
was assessed by one-way Anova and was assigned as *p< 0.05, **p
< 0.01, ***p < 0.001. c, d Representative images of N-cadherin
(green, c) immunofluorescence or phalloidin staining shown to
visualize F-actin (red, d) cellular localization, with DAPI staining in
blue. Bars represent 20 µm. Experiments performed in biological
triplicate
Snail links LXR to TGFβ actions in HCC
evidence so far supports a model whereby regulation of
Snail expression by LXRα is mainly at the transcriptional-
promoter level (Figs. 2 and 3). Snail regulates mesenchymal
genes and actin fiber organization. LXR agonistic activation
suppressed N-cadherin-based junctions and actin stress
fibers (Fig. 4), responses supported by endogenous LXRα
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(Fig. 5). Previous work in LXRα−/− mice established higher
Snail expression in epithelial cells surrounding the fibrous
bulbs in the ventral prostate [21]. In contrast, in lung ade-
nocarcinoma cells, 25-hydroxycholesterol weakly induced
Snail expression via activation of both LXRs [22]. How-
ever, these studies did not examine whether these
mechanisms involved transcriptional regulation.
Interestingly, LXRα activation by its agonist enhanced
the well-established cytostatic effect of TGFβ in epithelial
hepatocarcinoma cells [23], by significantly decreasing their
viability and proliferation (Fig. 6). The cytostatic effect of
TGFβ is based on a block in the G1 to S phase transition,
which was corroborated in this study also based on
enhanced induction of the cell cycle inhibitor p21CIP1 and
decrease in cyclin E levels (Fig. 6). These negative effects
of LXRα activation on HCC proliferation agree with pre-
viously reported findings of LXRα on cell cycle progression
in diverse carcinomas [24–27]. The literature frequently
equates cytostasis induced by TGFβ to its pro-apoptotic
capacity [2,4]. The evidence provided here clearly distin-
guishes between these two processes. Whereas LXRα
activation enhanced the cytostatic effect of TGFβ, it sup-
pressed pro-apoptotic responses to TGFβ, and even
enhanced the expression of pro-survival genes (Fig. 7). Pro-
survival molecules such as BCL2, MCL1, and more, can be
induced by TGFβ signaling in HCC models, presumably
due to a mechanism that aims at counterbalancing pro-
apoptotic signals mediated by the same cytokine [4,28,29].
Part of the pro-apoptotic response of HCC to TGFβ is the
generation of ROS via the transcriptional induction of
NOX4 [30,31]. Even on this front, our study establishes
how LXR signaling suppresses the ability of TGFβ to
induce NOX4 expression and ROS production (Fig. 7). This
provides an additional mechanism by which LXR signaling
may counteract pro-apoptotic events in HCC. Thus, LXRα
cooperates with TGFβ signaling to generate a strong
negative effect on cell proliferation, whereas LXRα antag-
onizes TGFβ with respect to the apoptotic response. This
evidence also suggests that LXRα does not act as a general
inhibitor of all TGFβ-mediated physiological actions, but
rather, that the two molecular systems interact in main-
taining an intermediate state of HCC differentiation and
survival, as represented by the apoptosis-resistant,
mesenchymal variants of HCC.
While Snail mediated expression of pro-survival BCL2
and MCL1 genes (Fig. 8), it was not important for the pro-
apoptotic generation of ROS, and only partially affected
NOX4 expression (Fig. 8), in agreement with previous
observations [30]. We propose that Snail participates only
in a subset of the molecular crosstalk between LXR and
TGFβ. Snail mediates TGFβ responses, such as EMT and
pro-survival gene expression, whereas the cooperation
between LXRα and TGFβ in mediating cytostasis is Snail-
independent. LXRα activation in HCC can be beneficial in
order to antagonize TGFβ signaling especially in late-stage
liver malignancies, via the promotion of a cytostatic, low-
mesenchymal HCC status. This could potentially lead to the
use of LXR agonists, already in clinical practice, for the
treatment of late-stage HCC.
Materials and methods
Cell culture
Hep3B, PLC/PRF5, HUH7, Snu449, Snu423, HLE, and
HLF cells have been described before [30,32]. Hep3B cells
were cultured in Minimum Essential Medium (Gibco,
Thermofisher Scientific, Stockholm, Sweden) supplemented
with 10% fetal bovine serum (FBS; Biowest, Almeco A/S,
Esbjerg, Denmark) and 100 U/ml penicillin, 100 μg/ml
streptomycin, 2 mM glutamine, and 0.1 mM non-essential
amino acids (Sigma-Aldrich AB, Stockholm, Sweden).
Snu449 and Snu423 were cultured in RPMI-1400 with
glutamax (Gibco), 10% FBS and 100 U/ml penicillin, 100
μg/ml streptomycin. PLC/PRF5, HUH7, HLE, HLF, and
HepG2 cells were cultured in Dulbecco’s modified Eagle
medium (Sigma-Aldrich AB) supplemented with 10% FBS
and 100 U/ml penicillin, 100 μg/ml streptomycin and 2 mM
glutamine (Sigma-Aldrich AB). Cells were kept in a
humidified incubator at 37 °C and 5% CO2.
Screening of compounds
Experiments with inhibitors were performed in 3% FBS-
containing medium. TGFβ1 (PeproTech EC Ltd, London,
UK), used at a final concentration of 5 ng/ml, was added at
the same time as the compounds. Ivermectin, GW3965,
GSK3987, WYE672, and GGsTOP (kindly provided by
Timothy C. Gahman and Andrew K. Shiau, Ludwig Insti-
tute for Cancer Research, La Jolla, CA, USA) were used at a
final concentration of 5 or 10 μM, and the TGFβ type I
Fig. 5 The antagonistic effect of T0901317 on mesenchymal proper-
ties depends on an active LXRα pathway. Snu449 cells were trans-
fected with non-targeting siControl and siLXRα targeting siRNA for
24 h and treated with TGFβ1 (5 ng/ml) with or without T0901317 (5
μM) in starvation medium for 24 h. a The expression of the indicated
proteins was assessed by immunoblotting. Experiments performed in
biological quadruplicate. Densitometric quantification is provided
graphically and basal expression levels set to 1 correspond to different
levels of N-cadherin and Snail protein expression, as visualized on the
immunoblots. Statistical significance was assessed by two-way Anova
and was assigned as *p< 0.05, ***p< 0.001. b, c Representative
images of N-cadherin (green, b) immunofluorescence or phalloidin
staining to visualize F-actin (red) cellular localization, with DAPI
staining in blue. Bars represent 20 µm. Experiments performed in
biological triplicate. All immunoblots indicate molecular size markers
in kDa; M stands for the molecular size marker lane
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receptor inhibitor LY2157299 (Cayman Chemical, Stock-
holm, Sweden), at a concentration of 2 μM. Controls were
treated with dimethylsulfoxide (Sigma-Aldrich AB), which
served as vehicle for dissolving the compounds. Cells were
serum-deprived for 16 h, and compounds were added at
80% cell confluency for 48 h. In the case of combination
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treatment, TGFβ1 and T0901317 were co-administered to
cells at 80% confluency for 24 h. The MAP-kinase inhibi-
tors used were the p38 MAPK inhibitor SB203580 (Cal-
biochem-Merck, Stockholm, Sweden) at final concentration
10 μM, the JNK inhibitor SP600125 (Calbiochem-Merck) at
final concentration 10 μM, and the MEK inhibitor
PD184352 (Sigma-Aldrich AB) at final concentration 0.5
μM. Snu449 were seeded at a density of 4× 105 cells in 60
mm culture dishes, serum-deprived for 16 h prior to treat-
ment with MAP-kinase inhibitors, which were added 1 h
prior to treatment with TGFβ1.
SDS-polyacrylamide gel electrophoresis and
immunoblotting
For protein extraction, 5× 105 (Hep3B) and 4× 105
(Snu449) cells were seeded in 60 mm culture dishes. After
the specified treatments, the cells were washed in ice-cold
phosphate buffered saline (PBS) pH 7.4 (SVA, Uppsala,
Sweden) and lysed in 0.5% Triton X-100, 0.5% sodium
deoxycholate, 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 10
mM EDTA, and 0.25 mM LiCl, supplemented with 25×
protease inhibitor cocktail (Roche Diagnostics Scandinavia
AB, Bromma, Sweden), 0.25 mM LiCl, 5 mM NaF, and 1
mM Na3VO4. Protein concentration was determined by
Bradford Assay (Bio-Rad, Hercules, CA, USA). SDS-
polyacrylamide gel electrophoresis was performed using
10% or 12% polyacrylamide gels; proteins were transferred
to nitrocellulose (0.45 μm) membranes, stained with 0.1%
Ponceau-S/5% acetic acid for 5 min at room temperature,
and blocked by incubation either in 5% milk or in 5%
bovine serum albumin in Tris-buffered saline (0.05 M Tris,
0.138M NaCl, 0.0027M KCl, pH 8.0), supplemented with
0.1% Tween 20 (TBS-T), for 1 h at 25 °C. Antibodies
against the following proteins were used at the indicated
dilutions in TBS-T: fibronectin, 1:10 000 (Sigma-Aldrich
AB, F3648); E-cadherin, 1:1000 (BD Biosciences, Stock-
holm, Sweden, 610182); N-cadherin, 1:1000 (BD Bios-
ciences, 610920); vimentin, 1:2000 (Sigma-Aldrich AB,
clone 13:2); claudin 3, 1:1000 (Zymed, Thermofisher Sci-
entific, Stockholm, Sweden, 34-1700); Snail, 1:1000 (Cell
Signaling Technology, Stockholm, Sweden, C15D3);
PARP1, 1:1000 (BD Pharmingen, Stockholm, Sweden,
556362); PAI1, 1:500 (Abcam, Cambridge, UK, ab66705);
pAKT D93 (Ser473), 1:1000 (Cell Signaling Technology,
4060); pan-AKT C67E7, 1:1000 (Cell Signaling Technol-
ogy, 4691); LXRα, 1:1000 (Abcam, ab41902); LXRβ,
1:1000 (Thermo Scientific Pierce, PA1-333); Cyclin E (M-
20), 1:200 (Santa Cruz Biotechnology, Dallas, TX, USA);
p21CIP1 (EPR362), 1:200 (Abcam, ab109520); GAPDH,
1:50 000 (Ambion, Thermofisher Scientific, Stockholm,
Sweden, AM4300); β-tubulin, 1:1000 (BD Pharmingen,
556321); Flag, 1:2000 (Sigma-Aldrich AB); and Myc,
1:5000 (Santa Cruz Biotechnology). Horseradish
peroxidase-conjugated anti-mouse, anti-rabbit, or anti-goat
secondary antibodies (Invitrogen, Thermofisher Scientific,
Stockholm, Sweden) were diluted 1:20 000 in TBS-T
solution. Protein bands were visualized by chemilumines-
cence with the Immobilon Western ECL reagent (Merck-
Millipore, Stockholm, Sweden) using the Chemidoc appa-
ratus (Bio-Rad). Densitometric quantification of the bands
was performed using Image J software (Image J, NIH).
Quantification was performed subtracting the background
signal and subsequently normalizing the band representing
the protein of interest vs. its loading control (GAPDH or β-
tubulin). It is worth noting that normalized expression under
basal conditions appears as 1, but this value corresponds to
high expression level (e.g., E-cadherin in Fig. 1a, left
panel), intermediate to strong expression level (e.g.,
vimentin in Fig. 1a, right panel), or even very low to almost
undetectable expression level (e.g., fibronectin in Fig. 1a,
left and right panels).
cDNA synthesis and real-time PCR
For RNA extraction, 5× 105 (Hep3B) and 4× 105
(Snu449) cells were seeded in 60 mm culture dishes. Total
RNA was isolated using the NucleoSpin RNA II kit
(Macherey Nagel, AH Diagnostics, Solna, Sweden)
according to the manufacturer’s instructions. The extracted
RNA was then DNAse I-treated (Life Technologies, Ther-
mofisher Scientific, Stockholm, Sweden) in order to elim-
inate DNA contaminations, according to the manufacturer’s
protocol. The extracted RNA was quantified on a NanoDrop
2000 (Thermofisher Scientific, Stockholm, Sweden) and 1
μg was reverse-transcribed to cDNA using the iScript
cDNA synthesis kit (Bio-Rad). Real-time PCR was per-
formed based on the primers listed in Supplementary
Fig. 6 TGFβ and LXRα additively suppress the proliferation of the
epithelial Hep3B cells. Hep3B cells were treated with TGFβ1 (5 ng/ml)
with or without T0901317 (5 μM) in starvation medium. a Hep3B cells
were treated for 48 h and subsequently MTS viability assay was per-
formed. The graph describes the percentage of cell viability related to
untreated cells, which is set to 100%, and values are mean± SD
values. Experiments performed in biological triplicate, each of them in
technical triplicate. b Hep3B cells were treated for 24 h, and immu-
nofluorescence staining for Ki67 was performed. Representative image
where Ki67 is represented in green, DAPI staining in blue. Bars
represent 20 µm. The percentage of Ki67-positive nuclei is graphed as
mean± SD values, for each condition. Experiments performed in
biological triplicate. c Hep3B cells were treated for 24 h, the expres-
sion of the indicated proteins was assessed by immunoblotting.
Experiments performed in biological triplicate. Densitometric quanti-
fication is provided graphically and basal expression levels set to 1
correspond to the different absolute levels of cyclin E and p21 protein
expression, as visualized on the immunoblots. Statistical significance
was assessed by one-way Anova. Significance was assigned as *p<
0.05, ***p< 0.001. All immunoblots indicate molecular size markers
in kDa
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Table 1, on a Bio-Rad CFX96 cycler using KAPA SYBR
FAST 2× MasterMix (KAPA, Roche Diagnostics Scandi-
navia AB) according to the manufacturer’s instructions. The
expression level of each target gene was normalized to the
endogenous reference gene GAPDH and calculated as 2−ΔCt
(ΔCt= Ctsample mRNA−CtGAPDH mRNA). Representative
results of at least three biological replicates in technical
triplicate are presented.
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Transient transfection with siRNA
Hep3B and Snu449 cells were seeded at a density of 1×
106 in 15 cm culture dishes and transiently transfected with
the indicated siRNA. Cells were transfected at ~80%
confluency in serum-free OptiMem (Gibco, Thermofisher
Scientific), and Mirus TransIT siQUEST (Mirus Biologi-
cal, Kem En Tech Diagnostics Nordics, Taastrup, Den-
mark) as transfection reagent, according to the
manufacturer’s guidelines. After 24 h cells were seeded for
subsequent experiments at specified densities, as descri-
bed. Where specified, cells where serum-starved for 16 h
and subsequently TGFβ1-treated with or without
T0901317 for the indicated time periods at 5 ng/ml and 5
µM, respectively. The used siRNAs were as follows:
siControl (ON-TARGETplus Non-targeting Pool #D-
001810-10-20, Dharmacon); siLXRα (ON-TARGETplus
Human NR1H3 siRNA SMARTpool L-003413-00-0005,
Dharmacon); and siSNAI1 (ON-TARGETplus Human
SNAI1 siRNA SMARTpool L-010847-01-0005,
Dharmacon).
Transient overexpression
Hep3B cells were seeded at a density of 5× 105 cells in 60
mm culture dishes and transient overexpression was per-
formed with the indicated plasmids (final total DNA of 1
μg). Cells were transfected at ~80% confluency using
OptiMem (Gibco, Thermofisher Scientific) and Mirus
TransITX2 (Mirus Biological, Kem En Tech Diagnostics
Nordics) as transfection reagent, according to the manu-
facturer’s guidelines. Transfection was performed for 24 h
and, where indicated, cells were subsequently serum-
starved for 16 h and then TGFβ1-treated (5 ng/ml) with or
without T0901317 (5 µM) for the indicated time periods.
The plasmids used were pCDNA3 as mock control,
pABCA1-luc, pCMX-LXRα, and pCMX-LXRα trunc, the
latter three as previously described [15], and pCMV-β-
galactosidase, phSnail-promoter-luc, pCDNA3-Flag-
Smad3, and pCDNA3-Flag-Smad4, as described [33].
Cytoplasmic-nuclear fractionation
Snu449 cells were seeded at a density of 4× 105 cells in 60
mm culture dishes. Cells were serum-deprived for 16 h prior
to treatments with TGFβ1 (5 ng/ml) and/or T0901317 (5
µM). In the case of combination treatment, TGFβ1 and
T0901317 were co-administered for 3 h. Treatments were
performed at 80% cell confluency. Nuclear fractionation
was performed using the CelLytic NuCLEAR Extraction
Kit (Sigma-Aldrich AB) according to the manufacturer’s
instructions. Proteins were identified via immunoblotting, as
described above.
Immunocytochemistry
Snu449 cells were seeded at a density of 3× 105 cells on
glass coverslips in six-well dishes, serum-deprived for 16 h
prior to treatments with TGFβ1 (5 ng/ml) and/or T0901317
(5 μM). Treatments were performed at 80% confluency for
N-cadherin and Snail staining and 60% confluency for Ki67
and phalloidin-actin staining. Cells were washed twice with
PBS and subsequently fixed in 4% formaldehyde/PBS for
30 min (Ki67, phalloidin-actin, and Snail stainings) or fixed
in ice-cold methanol:acetone for 10 min (N-cadherin stain-
ing). Cells were washed three times with PBS, permeabi-
lized with freshly made 0.5% Triton X-100/PBS for 10 min,
subsequently washed three times with PBS, and blocked
with 5% FBS/PBS–0.1 M glycine for 16 h at 4 °C. Slides
were washed three times with PBS and subsequently incu-
bated with primary antibodies in 5% FBS/PBS–0.1 M gly-
cine for 3 h or phalloidin for 30 min at room temperature
(25 °C). The fixed cells were incubated with the appropriate
Alexa Fluor-488 secondary antibody (Invitrogen, Thermo-
fisher Scientific) at a dilution of 1:1000 in PBS for 1 h in the
Fig. 7 LXRα signaling negatively affects TGFβ induction of early and
late apoptosis in Hep3B and Snu449, while inducing pro-survival
genes in Hep3B cells. Cells were treated with TGFβ1 (5 ng/ml) with or
without T0901317 (5 μM) in starvation medium. a Hep3B cells were
treated for 24 h and subsequently stained with propidium iodide (PI), a
late apoptosis detection assay. Representative pictures are shown with
PI-positive cells (red). Bars represent 60 µm. Quantification of per-
centage of PI-positive nuclei is graphed as mean± SD values.
Experiments performed in biological triplicate, each of them in tech-
nical duplicate. b Hep3B cells (left) and Snu449 cells (right) were
treated as described in the methods for 16 h and subsequently the
caspase 3 cleavage assay was performed, indicative of early apoptosis
events. Quantification of caspase activity normalized to protein content
per time unit is graphed as mean± SD values. Experiments performed
in biological triplicate, each of them in technical duplicate. c Hep3B
cells were treated for 24 h, the expression of the indicated proteins was
assessed by immunoblotting. Experiments performed in biological
triplicate. Densitometric quantification is provided graphically, and
basal expression levels set to 1 correspond to the levels of pAKT
protein in the presence of vehicle treatment, as visualized on the
immunoblot. All immunoblots indicate molecular size markers in kDa.
d Hep3B cells were treated in starvation medium for 16 h, as described
in the methods. The expression of the indicated genes was assessed via
real-time PCR and is graphed as mean± SD values, and basal
expression levels set to 1 correspond to different absolute levels of
BCL2 or MCL1 mRNA expression. Experiments performed in biolo-
gical triplicate, each of them in technical triplicate. e After 4 h of
treatment, the total amount of reactive oxygen species was quantified
by H2DCFDA fluorimetric quantification. Data are presented as per-
centage vs. control, which is set to 100%, and are mean± SD.
Experiments performed in biological quadruplicate, each of them in
technical duplicate. f Upon 16 h treatment, the expression of NOX4
mRNA was assessed via real-time PCR, and results are shown as
mean± SD. Experiments performed in biological triplicate, each of
them in technical triplicate. Statistical significance was assessed by
one-way Anova. Significance assigned **p< 0.01, ***p< 0.001
Snail links LXR to TGFβ actions in HCC
dark, at room temperature. Finally, incubation with 4′,6-
diamidino-2-phenylindole (Sigma-Aldrich AB) at a dilution
of 1:1000 in PBS was performed for 5 min. Coverslips were
mounted on microscope slides with Fluoromount G
(SouthernBiotech, AH Diagnostics, Solna, Sweden) and
observed on a Nikon Eclipse 90i fluorescence microscope.
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Primary images were acquired using the NIS elements
software. The primary reagents used for staining were
antibodies against Snail (1:200 dilution; Cell Signaling
Technology, C15D3), N-cadherin (1:200 dilution; BD
Biosciences, 610920), Ki67 (1:200 dilution; Abcam,
ab15580), and TRITC-conjugated phalloidin (1:1000 dilu-
tion; Sigma-Aldrich AB).
Luciferase assay
HepG2 cells were seeded at a density of 18× 103 cells in
24-well dishes. Cells were transfected with a human SNAIL
promoter construct encompassing approximately 900 bp
fused to the luciferase cDNA [33] or the proximal promoter
of the LXRα target gene ATP binding cassette transporter
A1 (ABCA1) fused to luciferase, together with pCMV-β-
galactosidase plasmid, the latter used as reference control, at
final amount of 100 ng per plasmid DNA. Transient over-
expression was performed with the indicated plasmids,
while transient silencing was conducted with the indicated
siRNAs at a final concentration of 30 nM. Transfection was
performed when cells were ~80% confluent for 48 h, as
explained above. Where indicated, cells were subsequently
serum-starved for 16 h and then TGFβ1 (5 ng/ml) or
T0901317 (5 μM), or a combination thereof were added for
the indicated time periods. Luciferase assay was performed
using the Firefly Luciferase Assay Kit (Biotium, Techtum,
Stockholm, Sweden) according to the manufacturer’s
instructions. β-Galactosidase activity was assessed via
quantification of conversion of its substrate o-nitrophenol-
glucose at 420 nm, and used as control. Chemiluminescent
and colorimetric readings were performed in an Enspire
Multimode multiwell 96-plate reader (Perkin Elmer, Upp-
lands Väsby, Sweden).
Cell viability (MTS) assay
Hep3B cells were seeded at a density of 8× 103 cells in 96-
well dishes, serum-starved for 16 h, and then, when they
had reached 80% confluency, were incubated with TGFβ1
(5 ng/ml) or T0901317 (5 μM), or a combination thereof for
48 h. Where indicated, Hep3B cells were seeded at a density
of 1× 106 cells in 15 cm dishes and transiently transfected
with the indicated siRNAs at a final concentration of 30 nM
for 24 h, as described above. Afterwards, cells were seeded
at the indicated concentration, serum-starved, and treated as
reported. MTS assay was performed using the CellTiter 96
AQueous One Solution Cell Proliferation Assay kit (Pro-
mega, Stockholm, Sweden) according to the manufacturer’s
instructions. The MTS solution was diluted in a 1:10 ratio
with cell media and the incubation was performed in dark
for 2 h in a humidified incubator at 37 °C, 5% CO2. The
absorbance of formazan salts was read at 490 nm in an
Enspire Multimode multiwell 96-plate reader (Perkin
Elmer). Representative results of at least three biological
replicates in technical triplicate are presented.
Caspase 3 activity assay (early apoptosis)
Hep3B cells were seeded at a density of 5× 105 cells in 60
mm dishes, serum-starved for 16 h, and then, when they had
reached 80% confluency, cells were incubated with TGFβ1
(5 ng/ml) or T0901317 (5 μM), or a combination thereof for
16 h. Where indicated, Hep3B cells were transiently trans-
fected with the indicated siRNAs, as previously described.
Afterwards, cells were seeded at the indicated concentra-
tion, serum-starved, and treated as reported. After treatment,
cell media was collected and cells were scraped in 3 ml PBS
(pH 7.4); cell media and lysates were centrifuged at 2500 r.
p.m. for 10 min at 4 °C. The pellet was then resuspended in
a solution containing 5 mM Tris-HCl pH 8, 20 mM EDTA,
0.5% Triton X-100, vortexed for 10 s, incubated on ice for
10 min, and centrifuged at 13 000 r.p.m. for 10 min at 4 °C.
Protein quantification was performed via Bradford Assay
(Bio-Rad). Proteins (25 μg) were resuspended in reaction
buffer, containing 1M HEPES (pH 7.5), 87% glycerol, 1 M
dithiothreitol, and the Ac-DEVD-AMC Caspase 3 fluoro-
genic substrate (BD Biosciences) was added at a con-
centration established by the manufacturer. Incubation was
then performed in dark for 2 h in a humidified incubator at
37 °C, 5% CO2. Fluorimetric analysis was performed in an
Enspire Multimode multiwell 96-plate reader (Perkin
Elmer). Fluorimetric caspase 3 activity was normalized vs.
Fig. 8 Snail regulates the expression of pro-survival genes BCL2 and
MCL1. Hep3B cells were transfected with non-targeting siControl and
siSnail targeting siRNA at a final concentration of 30 nM for 24 h and
subsequently seeded for the specified experiments, then cells were
treated with TGFβ1 (5 ng/ml) with or without T0901317 (5 μM) in
starvation medium. a Cells were treated for 48 h and the cell viability
was assessed by MTS assay. The graph reports the percentage of cell
viability related to untreated cells transfected with siCtrl, which is set
to 100%, as mean± SD values. Experiments performed in biological
triplicate, each of them in technical triplicate. b Hep3B cells were
treated for 16 h, then caspase 3 cleavage assay was performed;
quantification of caspase activity normalized to protein content per
time unit is graphed as mean± SD values. Experiments performed in
biological triplicate, each of them in technical duplicate. c After 4 h of
treatment, H2DCFDA fluorimetric quantification was performed. Data
are presented as percentage vs. control, which is set to 100%, and are
mean± SD. Experiments performed in biological quadruplicate, each
of them in technical duplicate. d–f Hep3B cells were incubated with or
without T0901317 for 16 h; the expression of genes of interest was
then analyzed by real-time PCR and the results are described as mean
± SD, with basal expression levels set to 1, corresponding to different
absolute levels of BCL2, MCL1, or SNAI1 mRNA expression.
Experiments performed in biological triplicate, each of them in tech-
nical triplicate. Statistical significance was assessed by one-way (b) or
two-way (a, c-f) Anova. Significance was assigned as *p< 0.05, **p
< 0.01, ***p< 0.001
Snail links LXR to TGFβ actions in HCC
the time of incubation of the substrate and the protein
content. Representative results of at least three biological
replicates in technical duplicate are presented.
PI assay (late apoptosis)
Hep3B cells were seeded at a density of 3× 105 cells in six-
well dishes, serum-starved for 16 h, and then, at 80% con-
fluency, cells were treated with TGFβ1 (5 ng/ml) or
T0901317 (5 μM), or a combination thereof for 24 h. PI
solution was then diluted in a 1:200 ratio with cell media
and the incubation was performed in the dark for 10 min in
a humidified incubator at 37 °C, 5% CO2. Incubation of PI
was performed serially for each condition and was imme-
diately followed by microscopic evaluation of each single
condition, in order to avoid excessive permeation of PI into
cells over prolonged time. Phase contrast images were
observed with a ×10 objective in a Zeiss Axioplan micro-
scope using a Zeiss Axioplan MRC digital camera. Primary




Hep3B cells were seeded at a density of 4× 104 cells in 12-
well dishes, serum-starved for 16 h, and then, at 80% con-
fluency, cells were treated with TGFβ1 (5 ng/ml) or
T0901317 (5 μM), or a combination thereof for 16 h. Where
indicated, Hep3B cells were transiently transfected with the
indicated siRNAs, as described above. Afterwards, cells
were seeded at the indicated concentration, serum-starved,
and treated as described. After treatment, cells were incu-
bated with 2.5 μM 2″,7′-dichlorodihydrofluorescein diace-
tate (Invitrogen, Thermofisher Scientific) in HBSS without
red phenol for 30 min. Cells were subsequently lysed with a
buffer containing 25 mM HEPES (pH 7.5), 60 mM NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, and 0.1% Triton X-100 for
10 min at 4 °C. Fluorescence analysis was performed in an
Enspire Multimode 96-well plate reader (Perkin Elmer).
Fluorescence values were normalized relative to the protein
content and are presented as percentage of control. Average
of four independent biological replicates in technical
duplicate is presented.
Statistical analysis
Experiments were performed in biological replicates, each
of which included at minimum technical triplicates, as
indicated in the figure legends. Representative results are
reported as averages minus-plus SD. Statistical analysis was
performed with GraphPadPrism (La Jolla, CA, USA) using
the specific analytical formula explained in the figure
legend, and statistical significance * was assigned with
p value< 0.05, **p< 0.01, ***p< 0.001.
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